A 12-month, Open Label, Multicenter Pilot Study Evaluating Fingolimod Treatment in terms of Patient Satisfaction in Relapsing Remitting Multiple Sclerosis Patients FINE Trial

Akman Demir, Gulsen; Turkoglu, Recai; Saip, Sabahattin; Yuceyar, Nur; EFENDİ, HÜSNÜ; TURAN, ÖMER; AĞAN YILDIRIM, KADRİYE; TERZİ, MURAT; BOZ, CAVİT; Tuncer, Asli; Kocer, Belgin; Kasap, Mithat; Caliskan, Zeynep

doi:10.5152/npa.2017.20515

A 12-month, Open Label, Multicenter Pilot Study Evaluating Fingolimod Treatment in terms of Patient Satisfaction in Relapsing Remitting Multiple Sclerosis Patients FINE Trial

Akman Demir G., Turkoglu R., Saip S., Yuceyar N., EFENDİ H., TURAN Ö. F., ...Daha Fazla

NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, cilt.56, sa.4, ss.253-257, 2019 (SCI-Expanded, Scopus, TRDizin)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 56 Sayı: 4
Basım Tarihi: 2019
Doi Numarası: 10.5152/npa.2017.20515
Dergi Adı: NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
Sayfa Sayıları: ss.253-257
Anahtar Kelimeler: Multiple sclerosis, fingolimod, patient satisfaction, quality of life, ORAL FINGOLIMOD, INTRAMUSCULAR INTERFERON, DOUBLE-BLIND, SAFETY, THERAPIES, EFFICACY, OUTCOMES, ACETATE, PHASE-3, SWITCH
Karadeniz Teknik Üniversitesi Adresli: Evet

Özet

Introduction: To assess satisfaction and quality of life in patients with relapsing-remitting multiple sclerosis (RRMS) who were receiving fingolimod (0.5 mg/day) for 12 months as a second-line treatment after switching from injectable agents.